Arrowhead Pharmaceuticals, Inc. (ARWR)
Stock Price:
$40.23 USD
-0.79 (-1.93%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $40.25 +0.02 (0.05%) Aug 7, 7:57 PM
Key Info
| Market Cap |
4.12B |
| Revenue (ttm) |
123.65M |
| Net Income (ttm) |
-24.42M |
| Shares Out |
102.29M |
| EPS (ttm) |
-0.25 |
| PE Ratio |
n/a |
| Forward PE |
46.95 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$40.23 |
| Previous Close |
$41.02 |
| Change ($) |
-0.79 |
| Change (%) |
-1.93% |
| Day's Open |
41.50 |
| Day's Range |
39.56 - 42.00 |
| Day's Volume |
921,836 |
| 52-Week Range |
19.51 - 73.72 |
More Stats
| Market Cap |
4.12B |
| Enterprise Value |
3.85B |
| Earnings Date (est) |
Dec 15, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
102.29M |
| Float |
99.71M |
| EPS (basic) |
-0.24 |
| EPS (diluted) |
-0.25 |
| FCF / Share |
-0.87 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.99M |
| Short Ratio |
8.16 |
| Short % of Float |
13.98% |
| Beta |
1.76 |
| PE Ratio |
n/a |
| Forward PE |
46.95 |
| P/FCF Ratio |
n/a |
| PS Ratio |
33.28 |
| PB Ratio |
8.87 |
| Revenue |
123.65M |
| Operating Income |
-33.40M |
| Net Income |
-24.42M |
| Free Cash Flow |
-88.63M |
| Net Cash |
265.66M |
| Net Cash / Share |
2.60 |
| Gross Margin |
136.51% |
| Operating Margin |
-27.01% |
| Profit Margin |
-19.70% |
| FCF Margin |
-71.68% |
| ROA |
-4.68% |
| ROE |
-6.80% |
| ROIC |
-21.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
6 |
| Overweight |
1 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$62.11*
(54.39% upside)
Low
29.0
Current: $40.23
High
81.0
Target: 62.11
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 169 | 16.14 | 31.41 | 0.16 | 0.38 | 0.18 | 0.29 | 0.15 | 0.30 | - |
| Revenue Growth | 945.67% | -48.6% | 19736.49% | -58.55% | 118.29% | -39.71% | 97.63% | -50.4% | - | - |
| Gross Profit | 169 | 16.14 | 31.41 | 0.16 | 0.38 | 0.18 | 0.29 | 0.15 | 0.30 | - |
| Operating Income | 61.19 | -55.94 | -37.00 | -87.61 | -94.08 | -50.90 | -23.17 | -21.09 | -9.83 | -5.83 |
| Net Income | 67.97 | -54.45 | -34.38 | -81.72 | -91.94 | -58.63 | -31.14 | -21.13 | -3.13 | -5.77 |
| Shares Outstanding | 93.86 | 83.64 | 73.90 | 61.05 | 57.36 | 46.93 | 24.00 | 11.13 | 7.18 | 6.43 |
| Earnings Per Share | 0.69 | -0.65 | -0.47 | -1.34 | -1.60 | -1.25 | -1.30 | -1.90 | -0.44 | -0.90 |
| Operating Cash Flow | 173 | -47.22 | -23.94 | -64.43 | -65.71 | -35.42 | -19.03 | -15.34 | -5.39 | -7.70 |
| Capital Expenditures | -12.00 | -1.42 | -7.92 | -3.86 | -1.97 | -1.71 | -0.21 | -0.19 | -0.01 | - |
| Free Cash Flow | 161 | -48.64 | -31.86 | -68.29 | -67.68 | -37.12 | -19.24 | -15.53 | -5.40 | -7.70 |
| Cash & Equivalents | 259 | 76.53 | 65.61 | 85.37 | 98.75 | 154 | 28.14 | 3.48 | 8.14 | 6.85 |
| Total Debt | - | 2.33 | 2.53 | 2.73 | 0.76 | 1.02 | 2.30 | 2.44 | 0.61 | 0.50 |
| Net Cash / Debt | 259 | 74.21 | 63.07 | 82.64 | 98.00 | 153 | 25.84 | 1.05 | 7.54 | 6.35 |
| Assets | 350 | 112 | 104 | 128 | 132 | 183 | 37.33 | 16.53 | 15.89 | 12.35 |
| Liabilities | 106 | 16.37 | 23.16 | 33.15 | 22.65 | 16.83 | 11.59 | 7.72 | 3.32 | 4.28 |
| Book Value | 245 | 95.80 | 81.42 | 95.58 | 110 | 167 | 27.50 | 10.01 | 12.79 | 9.05 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Arrowhead Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
134 |
| CEO |
Christopher Richard Anzalone |
Stock Information
| Ticker Symbol |
ARWR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARWR |
| IPO Date |
June 16, 1993 |
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.